House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Executive Summary
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
You may also be interested in...
Glucophage Provision Likely To Remain In Final Pediatric Exclusivity Bill
The Glucophage provision is likely to be included in the final version of pediatric exclusivity reauthorization legislation with no substantive changes
Glucophage Provision Likely To Remain In Final Pediatric Exclusivity Bill
The Glucophage provision is likely to be included in the final version of pediatric exclusivity reauthorization legislation with no substantive changes
Glucophage Provision In HR 2887 Could Be Breach Of Contract – Bristol
A recent Supreme Court ruling related to the savings & loan industry bailout could serve as a precedent for legal challenges by Bristol-Myers Squibb to the Glucophage provision in the pediatric exclusivity reauthorization legislation